Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 45

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 45
---
. Stock Options The Compensation Committee uses stock options as a key tool in serving to align the interests of our executive officers and our stockholders. Stock options are inherently performance based, and automatically link executive pay to stockholder return, as the value realized, if any, by the executive from an award of stock options, is dependent upon, and directly proportionate to, appreciation in stock price. Executives will only receive value from the stock option awards if the price of the stock increases above the stock price at time of grant, and remains above as the stock options continue to vest. Stock options also do not have downside protection, and the awards will not provide value to the holder when the stock price is below the exercise price. Restricted Stock Units The Compensation Committee uses RSUs in addition to stock options, as they are complementary to stock options and encourage alignment with stockholders' interests, while also reinforcing an ownership culture and ensuring adequate retention of our executive team. In January 2024, the Compensation Committee approved the following equity grants to our named executive officers as part of our annual executive compensation review process. The stock options vest monthly over a period of four years, subject to the recipient’s continued service to us through each vesting date, and the RSUs vest in four equal annual installments on a pre-specified vesting date, subject to the recipient’s continued service to us through each vesting date.

| Name                    |     | Stock Option 
        Grant 
          (#) |     | RSU Grant 
       (#) |
| Marshall Fordyce, M.D.  |     |      292,500 |     |    78,750 |
| Jason Carter(1)         |     |            — |     |         — |
| Robert Brenner, M.D.(1) |     |            — |     |         — |

| (1) | Mr. Carter and Dr. Brenner each commenced employment with us in 2024 and their equity compensation for 2024 was in the form of individually negotiated new hire awards made as an inducement material to each such officer entering into employment with us. The Compensation Committee has reviewed market data and believes these awards were in line with grants made in similar hiring situations by similarly situated companies. |

30

TABLE OF CONTENTS

Summary Compensation Table The following table presents all of the compensation awarded to or earned by or paid to our named executive officers during the years indicated below.

| Name and Principal Position           |      |     | Year |         |     |